Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Growth deficits in cystic fibrosis mice begin in utero prior to IGF-1 reduction.

Darrah R, Bederman I, Vitko M, Valerio DM, Drumm ML, Hodges CA.

PLoS One. 2017 Apr 6;12(4):e0175467. doi: 10.1371/journal.pone.0175467. eCollection 2017.

2.

Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.

Hsu D, Taylor P, Fletcher D, van Heeckeren R, Eastman J, van Heeckeren A, Davis P, Chmiel JF, Pearlman E, Bonfield TL.

Infect Immun. 2016 Aug 19;84(9):2410-21. doi: 10.1128/IAI.00284-16. Print 2016 Sep.

3.

Early pulmonary disease manifestations in cystic fibrosis mice.

Darrah RJ, Mitchell AL, Campanaro CK, Barbato ES, Litman P, Sattar A, Hodges CA, Drumm ML, Jacono FJ.

J Cyst Fibros. 2016 Nov;15(6):736-744. doi: 10.1016/j.jcf.2016.05.002. Epub 2016 May 24.

4.

Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Kim N, Duncan GA, Hanes J, Suk JS.

J Control Release. 2016 Oct 28;240:465-488. doi: 10.1016/j.jconrel.2016.05.031. Epub 2016 May 16. Review.

5.

Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections.

Cigana C, Lorè NI, Riva C, De Fino I, Spagnuolo L, Sipione B, Rossi G, Nonis A, Cabrini G, Bragonzi A.

Sci Rep. 2016 Feb 17;6:21465. doi: 10.1038/srep21465.

6.

Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator.

Zhang PX, Murray TS, Villella VR, Ferrari E, Esposito S, D'Souza A, Raia V, Maiuri L, Krause DS, Egan ME, Bruscia EM.

J Immunol. 2013 May 15;190(10):5196-206. doi: 10.4049/jimmunol.1201607. Epub 2013 Apr 19.

7.

Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response.

Bragonzi A, Farulla I, Paroni M, Twomey KB, Pirone L, Lorè NI, Bianconi I, Dalmastri C, Ryan RP, Bevivino A.

PLoS One. 2012;7(12):e52330. doi: 10.1371/journal.pone.0052330. Epub 2012 Dec 21.

8.

Response of CFTR-deficient mice to long-term chronic Pseudomonas aeruginosa infection and PTX3 therapy.

Paroni M, Moalli F, Nebuloni M, Pasqualini F, Bonfield T, Nonis A, Mantovani A, Garlanda C, Bragonzi A.

J Infect Dis. 2013 Jul;208(1):130-8. doi: 10.1093/infdis/jis636. Epub 2012 Oct 18.

9.

Infection, inflammation and host carbohydrates: a Glyco-Evasion Hypothesis.

Kreisman LS, Cobb BA.

Glycobiology. 2012 Aug;22(8):1019-30. doi: 10.1093/glycob/cws070. Epub 2012 Apr 5. Review.

10.

Cystic fibrosis: a mucosal immunodeficiency syndrome.

Cohen TS, Prince A.

Nat Med. 2012 Apr 5;18(4):509-19. doi: 10.1038/nm.2715. Review.

11.

Variation in MSRA modifies risk of neonatal intestinal obstruction in cystic fibrosis.

Henderson LB, Doshi VK, Blackman SM, Naughton KM, Pace RG, Moskovitz J, Knowles MR, Durie PR, Drumm ML, Cutting GR.

PLoS Genet. 2012;8(3):e1002580. doi: 10.1371/journal.pgen.1002580. Epub 2012 Mar 15.

12.

Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells.

Parker D, Cohen TS, Alhede M, Harfenist BS, Martin FJ, Prince A.

Am J Respir Cell Mol Biol. 2012 Jan;46(1):6-13. doi: 10.1165/rcmb.2011-0080OC.

13.

Critical role of CFTR-dependent lipid rafts in cigarette smoke-induced lung epithelial injury.

Bodas M, Min T, Vij N.

Am J Physiol Lung Cell Mol Physiol. 2011 Jun;300(6):L811-20. doi: 10.1152/ajplung.00408.2010. Epub 2011 Mar 4.

14.

HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression.

Conrad D, Wang A, Pieters R, Nicoletti F, Mangano K, van Heeckeren AM, White SK, Frincke JM, Reading CL, Stickney D, Auci DL.

J Inflamm (Lond). 2010 Oct 30;7:52. doi: 10.1186/1476-9255-7-52.

15.

Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR.

Am J Respir Cell Mol Biol. 2011 Jun;44(6):922-9. doi: 10.1165/rcmb.2010-0224OC. Epub 2010 Aug 19.

16.

Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novo cholesterol synthesis.

Fang D, West RH, Manson ME, Ruddy J, Jiang D, Previs SF, Sonawane ND, Burgess JD, Kelley TJ.

Respir Res. 2010 May 20;11:61. doi: 10.1186/1465-9921-11-61.

17.

Leukotriene B4 mediates gammadelta T lymphocyte migration in response to diverse stimuli.

Costa MF, de Souza-Martins R, de Souza MC, Benjamim CF, Piva B, Diaz BL, Peters-Golden M, Henriques Md, Canetti C, Penido C.

J Leukoc Biol. 2010 Feb;87(2):323-32. doi: 10.1189/jlb.0809563. Epub 2009 Oct 30.

18.

Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages.

Deriy LV, Gomez EA, Zhang G, Beacham DW, Hopson JA, Gallan AJ, Shevchenko PD, Bindokas VP, Nelson DJ.

J Biol Chem. 2009 Dec 18;284(51):35926-38. doi: 10.1074/jbc.M109.057372.

19.

16alpha-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs.

Nicoletti F, Conrad D, Wang A, Pieters R, Mangano K, van Heeckeren A, White SK, Frincke J, Reading CL, Auci DL, Stickney D.

Clin Exp Immunol. 2009 Dec;158(3):308-16. doi: 10.1111/j.1365-2249.2009.04032.x. Epub 2009 Sep 30.

20.

The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.

Nichols DP, Ziady AG, Shank SL, Eastman JF, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L828-36. doi: 10.1152/ajplung.00171.2009. Epub 2009 Aug 21.

Supplemental Content

Support Center